Bloomberg News

Regeneron Pharmaceuticals to Replace MetroPCS in S&P 500 Index

April 24, 2013

Regeneron Pharmaceuticals Inc. (REGN:US), maker of the Eylea eye medicine, will replace MetroPCS Communications Inc. in the Standard & Poor’s 500 Index, S&P said in a statement today.

The change will take place after the close of trading on April 30, S&P said.

MetroPCS is merging with Deutsche Telekom AG’s T-Mobile USA Inc. in a transaction that is expected to leave the combined company’s public float below the 50 percent threshold needed for inclusion in the index, S&P said. MetroPCS shareholders approved the sweetened deal today in a crucial vote that gives Deutsche Telekom a chance to revive its U.S. business.

To contact the reporter on this story: Jeff Sutherland in New York at

To contact the editor responsible for this story: Lynn Thomasson at

We Almost Lost the Nasdaq

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • REGN
    (Regeneron Pharmaceuticals Inc)
    • $306.02 USD
    • 2.29
    • 0.75%
Market data is delayed at least 15 minutes.
blog comments powered by Disqus